Peptide YY regulates bone remodeling in mice: A link between gut and skeletal biology

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Wong, Iris P L ^a   Driessler, Frank ^a   Khor, Ee Cheng ^a   Shi, Yan Chuan ^a   Hörmer, Birgit ^a   Nguyen, Amy D ^a   Enriquez, Ronaldo F ^a   Eisman, John A ^a,b   Sainsbury, Amanda ^a,b   Herzog, Herbert ^a,b   Baldock, Paul A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE YY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE MASS; BONE REMODELING; BONE STRUCTURE; CELL ACTIVITY; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR DYNAMICS; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PEPTIDE YY GENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENE ORDER; GENE TARGETING; MALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; PEPTIDE YY; SIGNAL TRANSDUCTION;

MUS;

EID: 84863655029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040038     Document Type: Article

References (42)

1. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22: 781-788.
2. Wong IP, Baldock PA, Herzog H, (2010) Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes 17: 44-50.
3. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, et al. (2005) Ghrelin directly regulates bone formation. J Bone Miner Res 20: 790-798.
4. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, et al. (2009) Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone.
5. Ding KH, Shi XM, Zhong Q, Kang B, Xie D, et al. (2008) Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 23: 536-543.
6. Wortley KE, Garcia K, Okamoto H, Thabet K, Anderson KD, et al. (2007) Peptide YY regulates bone turnover in rodents. Gastroenterology 133: 1534-1543.
7. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, et al. (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825-837.
8. Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, et al. (2010) Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 25: 2078-2088.
9. Fleischer J, Stein EM, Bessler M, Della Badia M, Restuccia N, et al. (2008) The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 93: 3735-3740.
10. Tsai WS, Inge TH, Burd RS, (2007) Bariatric surgery in adolescents: recent national trends in use and in-hospital outcome. Arch Pediatr Adolesc Med 161: 217-221.
11. Misra M, Miller KK, Tsai P, Gallagher K, Lin A, et al. (2006) Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 91: 1027-1033.
12. Russell M, Stark J, Nayak S, Miller KK, Herzog DB, et al. (2009) Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. Bone 45: 104-109.
13. Scheid JL, Toombs RJ, Ducher G, Gibbs JC, Williams NI, et al. (2011) Estrogen and peptide YY are associated with bone mineral density in premenopausal exercising women. Bone 49: 194-201.
14. Utz AL, Lawson EA, Misra M, Mickley D, Gleysteen S, et al. (2008) Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 43: 135-139.
15. Ekblad E, Sundler F, (2002) Distribution of pancreatic polypeptide and peptide YY. Peptides 23: 251-261.
16. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654.
17. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, et al. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948.
18. Reid IR, (2002) Relationships among body mass, its components, and bone. Bone 31: 547-555.
19. Pournaras DJ, Osborne A, Hawkins SC, Mahon D, Ghatei MA, et al. (2010) The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg 20: 56-60.
20. Valderas JP, Irribarra V, Boza C, de la Cruz R, Liberona Y, et al. (2010) Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab 95: 1069-1075.
21. Viegas M, Vasconcelos RS, Neves AP, Diniz ET, Bandeira F, (2011) Bariatric surgery and bone metabolism: a systematic review. Arq Bras Endocrinol Metabol 54: 158-163.
22. Bose M, Machineni S, Olivan B, Teixeira J, McGinty JJ, et al. (2010) Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring) 18: 1085-1091.
23. von Mach MA, Stoeckli R, Bilz S, Kraenzlin M, Langer I, et al. (2004) Changes in bone mineral content after surgical treatment of morbid obesity. Metabolism 53: 918-921.
24. Wucher H, Ciangura C, Poitou C, Czernichow S, (2008) Effects of weight loss on bone status after bariatric surgery: association between adipokines and bone markers. Obes Surg 18: 58-65.
25. Rapuri PB, Gallagher JC, Haynatzki G, (2004) Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab 89: 4954-4962.
26. Boey D, Lin S, Karl T, Baldock P, Lee N, et al. (2006) Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49: 1360-1370.
27. Hayashi S, McMahon AP, (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 244: 305-318.
28. Baldock PA, Lee NJ, Driessler F, Lin S, Allison S, et al. (2009) Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 4: e8415.
29. Allison SJ, Baldock P, Sainsbury A, Enriquez R, Lee NJ, et al. (2006) Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem 281: 23436-23444.
30. Lundberg P, Koskinen C, Baldock PA, Lothgren H, Stenberg A, et al. (2007) Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction. Biochem Biophys Res Commun 352: 444-448.
31. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, et al. (2002) Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109: 915-921.
32. Shi YC, Lin S, Wong IP, Baldock PA, Aljanova A, et al. (2010) NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 5: e11361.
33. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, et al. (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6: 980-984.
34. Hegde SS, Bonhaus DW, Stanley W, Eglen RM, Moy TM, et al. (1995) Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist. J Pharmacol Exp Ther 275: 1261-1266.
35. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF, (2002) JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 115: 4317-4325.
36. Yuzuriha H, Inui A, Asakawa A, Ueno N, Kasuga M, et al. (2007) Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development. Faseb J 21: 2108-2112.
37. Shi YC, Hämmerle C, Lee JI-C, Turner N, Nguyen AD, et al. (2012) Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity. Neuropeptides In Press.
38. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, et al. (2005) A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 202: 1527-1538.
39. Igwe JC, Jiang X, Paic F, Ma L, Adams DJ, et al. (2009) Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 108: 621-630.
40. Lee NJ, Doyle KL, Sainsbury A, Enriquez RF, Hort YJ, et al. (2010) Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res 25: 1736-1747.
41. Lee NJ, Nguyen AD, Enriquez RF, Doyle KL, Sainsbury A, et al. (2010) Osteoblast specific Y1 receptor deletion enhances bone mass. Bone.
42. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, et al. (2007) Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 282: 19092-19102.